Zosano Pharma Completes Manufacture of M207 Registration Batches
19 sept. 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid...
Zosano Pharma to Present Phase 3 Safety Study Update for ADAM™ Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference
06 sept. 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and...
Zosano Pharma and Collaborators to Present Efficacy Data for M207 in the Treatment of Migraine at the 17th Biennial Migraine Trust International Symposium (MTIS)
05 sept. 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid...
Zosano Pharma Reports Second Quarter 2018 Financial Results and Operational Update
09 août 2018 16h00 HE
|
Zosano Pharma Corporation
Completed enrollment for our M207-ADAM study with 344 subjectsPresented additional analyses from the ZOTRIP pivotal study on pain relief and recurrence at the 2018 American Headache Society (AHS)...
Zosano Pharma to Host Conference Call on Second Quarter 2018 Financial Results and Provide Operational Update
02 août 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic...
Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM™ Technology for the Delivery of Zolmitriptan
17 juil. 2018 08h30 HE
|
Zosano Pharma Corporation
Peer-reviewed article published in Journal of Pharmaceutical Science evaluates skin tolerability and bioavailability of ADAM’s intracutaneous zolmitriptan delivery FREMONT, Calif., July 17, 2018...
Zosano to Present Additional Analyses from the ZOTRIP Pivotal Study on Pain Relief and Recurrence at the 2018 American Headache Society (AHS) Meeting
27 juin 2018 14h00 HE
|
Zosano Pharma Corporation
Key findings on receptor and binding kinetics also to be presented in a poster and oral presentation FREMONT, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma, a clinical-stage...
Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics
20 juin 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic...
Zosano Announces Publication of Most Bothersome Symptom Data from the ZOTRIP Pivotal Study in Headache: The Journal of Head and Face Pain
23 mai 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic...
Zosano Appoints Steven A. Elms to Board of Directors
22 mai 2018 08h30 HE
|
Zosano Pharma Corporation
FREMONT, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic...